In 2022, 15 pharmacy benefit managers (PBMs) reported receiving payments from pharmaceutical drug manufacturers, which included rebates, fees, and price protection payments.
TDI collected the data under Texas Insurance Code 1369.502. TDI only reports what the PBMs supply and doesn’t audit it.
All rebates, fees, and payments collected from pharmaceutical drug manufacturers.
PBMs reported $4.39 billion in rebates, fees, and payments.
$4.39 billion is lower than total expected when combining the other three submissions below. This is due to two of the PBMs reporting lower amounts for this item than the total of their other three submissions.
All rebates, fees, and payments collected from pharmaceutical drug manufacturers passed to health benefit plan issuers.
PBMs reported $3.99 billion in rebates, fees, and payments passed to health benefit plan issuers.
All rebates, fees, and payments collected from pharmaceutical drug manufacturers passed to enrollees.
PBMs reported $866 thousand in rebates, fees, and payments passed to enrollees.
All rebates, fees, and payments collected from pharmaceutical drug manufacturers kept as revenue by the PBM.
PBMs reported $409 million kept as revenue.